N-cyclopropyl-4-[8-(4-hydroxybutylsulfanyl)-6-phenylimidazo[1,2-a]pyrazin-3-yl]benzamide
C26H26N4O2S — CID 53373574
Data last refreshed: (MolForge compound catalog, from PubChem)
About N-cyclopropyl-4-[8-(4-hydroxybutylsulfanyl)-6-phenylimidazo[1,2-a]pyrazin-3-yl]benzamide
N-cyclopropyl-4-[8-(4-hydroxybutylsulfanyl)-6-phenylimidazo[1,2-a]pyrazin-3-yl]benzamide (PubChem CID 53373574) has the molecular formula C26H26N4O2S and a molecular weight of 458.59 g/mol. Its IUPAC name is N-cyclopropyl-4-[8-(4-hydroxybutylsulfanyl)-6-phenylimidazo[1,2-a]pyrazin-3-yl]benzamide.
Molecular Properties
| Compound Name | N-cyclopropyl-4-[8-(4-hydroxybutylsulfanyl)-6-phenylimidazo[1,2-a]pyrazin-3-yl]benzamide |
|---|---|
| PubChem CID | 53373574 |
| Molecular Formula | C26H26N4O2S |
| Molecular Weight | 458.59 g/mol |
| Exact Mass | 458.18 |
| IUPAC Name | N-cyclopropyl-4-[8-(4-hydroxybutylsulfanyl)-6-phenylimidazo[1,2-a]pyrazin-3-yl]benzamide |
| SMILES | O=C(NC1CC1)c1ccc(-c2cnc3c(SCCCCO)nc(-c4ccccc4)cn23)cc1 |
| InChI | InChI=1S/C26H26N4O2S/c31-14-4-5-15-33-26-24-27-16-23(30(24)17-22(29-26)18-6-2-1-3-7-18)19-8-10-20(11-9-19)25(32)28-21-12-13-21/h1-3,6-11,16-17,21,31H,4-5,12-15H2,(H,28,32) |
| InChIKey | RPTPSKRGRWJUQP-UHFFFAOYSA-N |
| XLogP | 4.82 |
| TPSA | 79.52 Ų |
| H-Bond Donors | 2 |
| H-Bond Acceptors | 6 |
| Rotatable Bonds | 9 |
| Heavy Atoms | 33 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 458.59 |
| LogP ≤ 5 | 4.82 |
| H-Bond Donors ≤ 5 | 2 |
| H-Bond Acceptors ≤ 10 | 6 |
Computed Properties (RDKit)
| Structural Alerts | {'alert_name': 'Aliphatic_long_chain', 'substructure': 'N/A'} |
|---|
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 53373574 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.